Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

Key facts

Sponsor

Sol-Gel Technologies, Ltd.

Intervention

Patidegib Topical Gel(drug)

Enrollment

140 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2026

Study locations (30)

• Northwest Arkansas Clinical Trials Center, Rogers, Arkansas, United States
• Center for Dermatology Clinical Research, Fremont, California, United States
• University of California Los Angeles (UCLA) - Center for Inflammatory Bowel Diseases - Westwood Location, Los Angeles, California, United States
• The Dermatology Center of Newport, Newport Beach, California, United States
• Stanford University - Lucille Packard's Children's Hospital, Redwood City, California, United States
• Yale University, New Haven, Connecticut, United States
• Dermatology Associates of Tallahassee, Tallahassee, Florida, United States
• University of South Florida Health, Tampa, Florida, United States
• The University of Chicago Medicine, Chicago, Illinois, United States
• The Johns Hopkins Hospital, Baltimore, Maryland, United States
• University of Michigan Health - Michigan Medicine - University Hospital, Ann Arbor, Michigan, United States
• Minnesota Clinical Study Center, New Brighton, Minnesota, United States
• MediSearch Clinical Trials, Saint Joseph, Missouri, United States
• Schweiger Dermatology P.C., Verona, New Jersey, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.